Not sure if this is what's causing drop, but obviously some folks are concerned. I am anxious to see how we trade on Monday, after options expiration.

Great idea. I'd be fine limiting to biotech, but why not small cap instead? I week ago, I would have said this is because my mnkd holdings will be so huge that I need to diversify out of bio.

"Merrill Lynch reportedly says Afrezza's potential as a complement to oral in the Type 2 market is uncertain. "

Are they saying this because of weight gain and hypos? Does this really override the benefits of reduced a1c?

to put that hedge in place before results come out. Like many on this board, I had good intentions but the PPS kept moving away and making a hedge too expensive.

Notice the P values are very strong. It will be difficult for the shorts to construct a hit piece on this data.

Leaving for rest of day but can check prices on phone.

Think about it. How easy (and typical to the point of being expected) would it have been for them to say "Due to the volume of data and the critical need to be as accurate as possible, the trial results are taking longer to interpret than originally planned. Results should be available before the end of September."

I am relieved and encouraged.

That should make for some interesting trading, especially the first option expiration following results release.